Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
This randomized phase II trial studies how well cisplatin works with or without veliparib in
treating patients with triple-negative breast cancer and/or BRCA mutation-associated breast
cancer that has come back or has or has not spread to the brain. Drugs used in chemotherapy,
such as cisplatin, work in different ways to stop the growth of tumor cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading.
Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. It is not yet known if cisplatin is more effective with or without veliparib in
treating patients with triple-negative and/or BRCA mutation-associated breast cancer.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.